Replies to post #632159 on NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

HyGro,

Thanks for the reply, but you are again reposting disinformation from Reddit.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172749240

Seek verifiable sources and consider refocusing on what matters. I believe that you are distracted from the vast significance of Liau’s work and the further development of this technology in combination with other technologies. DCVax-L is already supported by peer-reviewed clinical evidence, but there is much more to the story that is yet to unfold, and the SP will follow the regulatory developments worldwide.

Targeted individualized combo therapies are emerging as the defining feature of a new era of oncology. Just look at the impact that PD1 blockade technology has had on the field of oncology in recent years!


https://www.fda.gov/drugs/news-events-human-drugs/50-years-progress-treating-patients-cancer

The P3 study of the DCVax-L cell-based platform technology is a landmark trial.

The P3 data were peer reviewed by independent physicians and qualified statisticians—please refer to JAMA Oncology. You might consider researching credible full-context sources to gather reliable information.

The DCVax-L cell-based technology has been under clinical investigation for a significant period of time, and the overall clinical data in total include three trials spanning many years. Safety and efficacy data have been gathered from trials with external controls and trials with placebo controls. The data include DCVax-L as a monotherapy and in combination with other agents.

The interim PD1 combo data are brilliant, and the trial is significant for a number of reasons relating to FDA guidelines and NIH peer-reviewed grant funding.



https://clinicaltrials.gov/ct2/show/NCT04201873

https://www.fda.gov/media/120721/download

In the combo trial, patients who receive DCVax-L + placebo are being compared to patients who receive DCVax-L + pembrolizumab.

The control arm is receiving DCVax-L. While DCVax-L is not the current SOC, it is highly significant and notable that DCVax-L is being permitted to fill the role of SOC as the best available therapy within this combo study for rGBM. The combo trial also follows the P3 in sequence which in itself validates the findings of the P3 study—the placebo group in the PD1 study would not be receiving DCVax-L today if the preceding P3 trial had not proven its efficacy.



The NIH is the most significant player in this game—If they had any doubt about the P3, the NIH would not continue their support and the FDA would not have permitted the combo trial to commence or continue.

https://clinicaltrials.gov/ct2/show/NCT04201873

The U.S. NIH has supported the DCVax-L platform for years, and the NIH renewed its support in 2022 to continue to fund the development of this technology and to fund research into combination therapies.

NIH-funded DCVax-L research is ongoing at UCLA today.

NIH grants are peer-reviewed and the research that NIH funds is highly scrutinized in advance of the award and also intermittently for the term of the various research projects.



Mr. Newirth is another DCVax-L survivor well surpassing 10 years following a 2012 diagnosis! Congratulations!

https://www.hawaii.edu/news/2017/03/30/newirth-laker-for-a-day/

June 13, 2023 Interview:

https://www.uclahealth.org/news/fda-approval-brain-cancer-alzheimers

Explore Professor Keyoumars Ashkan's passion for neurosurgery and his love for @KingsCollegeNHS below as part of their #BrilliantPeople series🧠👇@KingsNeuro @KingsIoPPN https://t.co/yGKt2681Ie

— King's College London (@KingsCollegeLon) May 25, 2022

https://brownneurosurgery.com/breakthrough-brain-cancer-vaccine/

https://www.theguardian.com/science/2022/nov/17/im-just-carrying-on-vaccine-gives-brain-cancer-patient-years-of-extra-life

https://www.braintumourresearch.org/stories/in-hope/in-hope-stories/kat-charles

https://www.uclahealth.org/news/brain-cancer-discovery-clinical-trials

https://www.uclahealth.org/news/ucla-received-590-million-in-nih-funding-second-highest-total-for-academic-medical-centers-in-2020



https://www.fda.gov/science-research/advancing-regulatory-science/fda-nih-joint-leadership-council-charter





September 2023







https://www.cns.org/annualmeeting

[QL300]

Murcidencel is the generic name, not DCVax. Not going to respond to the rest of your garbage as it’s a waste of time.

[Dr Bala]

Oh no, fudster HyGro is joining the other fudsters about the nonsense about ATL DC not being DCVax-L. The fudsters don't know diddly squat.

[Roman516]

It is getting old with more spin with no limits HG.

As a scientist who supports collaboration effort, it is fantastic news to see that Dr. Linda Liau had
joined with NWBO's SAB team. The effort is imperative to continue to help make NWBO move forward with great profession team based on Dr. Liau's team at UCLA. Perhaps you need to read the full story regarding Dr. Linda Liau joined NWBO's SAB team.

https://finance.yahoo.com/news/northwest-biotherapeutics-announces-dr-linda-140000962.html

"BETHESDA, Md., Sept. 12, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announces that Dr. Linda Liau, MD, PhD, MBA has joined the Company's Scientific Advisory Board (SAB).

Dr. Liau served as the Principal Investigator of the Phase 3 trial of DCVax®-L for treatment of glioblastoma. She is Chair of the Department of Neurosurgery at UCLA, Professor and Director of the UCLA Brain Tumor Program. Dr. Liau is the former Editor-in-Chief of the Journal of Neuro-Oncology. She is the Director of the UCLA Brain Cancer SPORE (Specialized Program of Research Excellence). She is an elected member of the National Academy of Medicine.

The longstanding members of the Company's Scientific Advisory Board include Dr. Samir Khleif, Dr. Jerome Galon and Dr. John Smyth, and also included Dr. Mac Cheever for many years until his passing.

Linda Powers, NWBio CEO, commented: "We are delighted to have Dr. Liau join our existing distinguished SAB. Her experience as a leader in the neuro-oncology field, her decades of research and knowledge of both brain cancer biology and immunotherapies, and her extensive experience with DCVax-L as the Principal Investigator of the Phase 3 trial, will be invaluable as we work together on DCVax-L approval and on future clinical programs building on that.""

BTW, had a great conversation with a friend in Washington DC last week about NWBO and Dr. Linda Liau jointing NWBO's SAB team. He was excited and indicated that this is great sign and supports the growing interest in the BIO sector for NWBO. Perhaps one is being confounded and it has blinded you to the fact that DCVax-L will move forward, and Dr. Linda Liau and the UCLA team are part of this growth as well, IMPO.

[jammy32]

Why so negative.

[learningcurve2020]

I believe you because you'd be pretty stupid to post a fake Prins email like you did and say this. Add to it the company has not come out to say it's not true, and pumpers here have done nothing but the usual circle jerk.

"Dr. Robert Prins of UCLA, one of the lead clinicians in the SPORE GBM Combo trial has confirmed that. All of the ATL manufacturing are using UCLA vendors and NONE of the NWBO vendors. Not Advent or Cognent."


Not necessarily. If the trial isn't being managed by NWBO the company may not want the name exposed just incase something goes wrong.

>> If it was UCLA would be obligated to call it DCVax-L as that is the generic name of the treatment. But they are NOT.

[muee88]

They are essentially the same, except made at different centers.

“… I mean they’re very similar. I don’t think there is a substantial difference — they’re just made at different centers, but the ones that we make here are made here and so otherwise there’s minor differences.” - Dr. Cloughesy

Dr. Cloughesy ALT-DC DCVAX "Similar" UCLA Virtual Brain Tumor Conference 05/06/2022 pic.twitter.com/8NWBw3ipmI

— LearningEveryTrade 🚀📈💰 (@EveryTrade) May 8, 2022

https://www.uclahealth.org/clinical-trials/pembrolizumab-and-vaccine-atl-dc-treatment-surgically

Principal Investigator
Timothy F. Cloughesy, MD

[The Danish Dude]

You sound confounded HyGro.

ATL-DC = DCVax-L, confirmed by Linds Liau in Al Musella webinar december 2022

33:57
Al Musella:
You talk about ATL-DC for the new trials. Is that the same thing as DCVax?

34:05
Linda Liau
Well, yeah DCVax-L is the trade name, that is actually licensed by Northwest Biotherapeutics.

34:12
Al Musella
It's the same process basically?

34:15
Linda Liau
Yes. So we develop the DCvax-L at UCLA.

[biosectinvestor]

We've discussed this before. There is no ambiguity here. UCLA is quite clear that ATL-DC IS in fact, DCVax-L. No one in authority, is confused. There is no need to distract people. Anonymous quotes from supposed emails from years ago, from someone ancillary to the trials, who wrote ambiguously, is simply not relevant or meaningful. It's NOT evidence in any respect. You could not, for instance, post this in a court of law. Nor would it be a relevant factor given all the other evidence, in a court of law.

To refresh your memory of our previous discussions:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172751150

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172694431

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172687235

[jammy32]

I’m really surprised that you’re so factual in your statements. Didn’t they chase away that low life stien guy for being so factual all the time.

Anyways , just my opinion

[LearningEveryTrade]

Hygro, Dr.Cloughesy Disagrees...